DRMA - Dermata Therapeutics, Inc. Common Stock

Day	1m	10m	60m	PreMarket	Market	AfterHours	Gap
4.15 0.21 (5.06%)	---	---	---	0.0 (0.0%)	0.08 (1.87%)	0.0 (0.0%)	-0.15 (-3.49%)

Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.

Category: PHARMACEUTICAL PREPARATIONS

Market Period: AfterHours

Earnings & Ratios

Basic EPS:: -0.45
Diluted EPS:: -0.45
Basic P/E:: -9.6889
Diluted P/E:: -9.6889
RSI(14) 1m:: 46.58
VWAP:: 4.35
RVol:: 0.1187

Events

Period	Kind	Movement	Occurred At
1m	Price decrease 1m	4.36 -0.04 (-1.02%)	Oct 15 15:51
1m	Price increase 1m	4.37 +0.05 (+1.16%)	Oct 15 15:23
1m	Price increase 1m	4.4 +0.07 (+1.62%)	Oct 15 15:15
1m	Price increase 1m	4.24 +0.05 (+1.3%)	Oct 15 13:19
1m	Price increase 1m	4.26 +0.06 (+1.34%)	Oct 15 12:57